![]() ![]() Johnson & Johnson had already fallen behind on deliveries of its one-shot COVID-19 vaccine to poorer countries. Other facilities have been tasked to produce the J&J vaccine, but they either still await regulatory approval or weren’t yet manufacturing it, the Times reported. While it’s unclear if the shutdown that began late last year has had an impact on vaccine availability, it could slash Johnson & Johnson’s supply by a few hundred million doses, one source told the newspaper. The stoppage at the plant in the Netherlands is temporary - with production of the vaccine expected to resume sometime in March, the New York Times reported, citing sources close to the matter. ![]() Johnson & Johnson stopped production of its single-shot COVID-19 vaccine at the only plant making usable doses late last year, according to a report Tuesday. Pro basketball player dies of heart attack after blaming COVID vaccine for rare heart conditionĭurham’s ‘chilling’ revelations, what RFK Jr. ![]() Realtors reveal the most insane demands NYC landlords have placed on would-be tenants Fauci with stinging impression: ‘I’m introducing the daily COVID shot’ government, executives said on the investor call.‘SNL’ Legend Dana Carvey hits Dr. The facility could make as many as 120 million doses a month at full capacity, but the finished doses might not be available until this fall, the Journal reported.Įmergent expects to launch in the near future a late stage study for a COVID-19 therapeutic it is developing in partnership with the U.S. The Wall Street Journal, which first reported the news, cited a letter from the FDA saying the agency had no objections with the plant resuming manufacturing. The FDA did not immediately respond to a Reuters request for comment. "We will continue to work toward securing Emergency Use Authorization in the United States for drug substance manufactured at Emergent Bayview as quickly as possible," J&J said in an email. J&J's vaccine, considered more convenient for use, storing and shipping to remote areas, has seen a relatively slow uptake in Europe and the United States due to safety concerns and the production issues. government can make decisions regarding the disposition of this material," Kramer said during the call.Īn FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices. "We continue to work collaboratively with AstraZeneca to complete all documents related to their drug substance so they and the U.S. government asked Emergent to stop making AstraZeneca shots after it discovered the cross contamination. health regulators in April halted operations at the Baltimore plant following a discovery that ingredients from AstraZeneca's (AZN.L) COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines. ![]() The FDA has so far approved five batches from the Emergent facility since production there was paused, and J&J is working to clear additional doses for use, the drugmaker said last week.Įmergent expects the FDA to approve additional batches of J&J shots, Kramer said during Emergent's Thursday investor call. The resumption follows additional reviews and collaboration with the FDA and manufacturing partners, Emergent Chief Executive Officer Robert Kramer said. Last week, J&J slashed 2021 production target of its single-dose vaccine to between 500 million and 600 million doses from its original goal to produce a billion shots. The development was announced late on Wednesday. July 29 (Reuters) - Emergent BioSolutions (EBS.N) said it will resume production of Johnson & Johnson's (JNJ.N) COVID-19 vaccine at its troubled Baltimore facility, where operations were stopped in April after millions of doses were found to be contaminated. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |